Skip to content

Patient and Staff Safety During Aorto-iliac Revascularization Procedures Under Automated Fusion Imaging Guidance With Controls

A Prospective Single Centre Randomized Interventional Controlled Trial Comparing Patient and Staff Safety During Aorto-iliac Revascularization Procedures Under Automated Fusion Imaging Guidance With Controls

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03713450
Acronym
CYDAR ILIAC
Enrollment
45
Registered
2018-10-19
Start date
2019-01-10
Completion date
2020-02-07
Last updated
2023-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient and Staff Radiation Exposure During Aorto-iliac Endovascular Revascularization

Keywords

Radiation, Contrast, Endovascular, Fusion imaging guidance, Iliac

Brief summary

Endovascular revascularization has revolutionized the field of vascular surgery and has become the first-choice treatment for peripheral arteries occlusive disease. However, the drawback of this technic is the X-ray exposure for both patients and staff and the iodinated contrast injection for the patient. One way to reduce both radiation and contrast use is to use advanced imaging techniques allowing an overlay of a 3D vascular mask (from a pre-operative CT scan) onto the live X-ray image. This has been proven during endovascular aneurysm repair. This advanced imaging application is currently available only in the latest expensive hybrid operating rooms, requires additional manoeuvre from the operator throughout the procedure, and may be X-rays and contrast consuming. This trial will examine the clinical benefits based on patient and staff' radiation exposure during aorto-iliac revascularisation, of a new software imaging guidance, suitable for any theatre including those equipped with mobile C-arm, fully automated and with a radiation free overlay registration process.

Interventions

DEVICEControl with imaging guidance

Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure using the automated overlay imaging guidance, in addition to the application of the ALARA principles. The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile).

DEVICEControl without imaging guidance

Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure not using the automated overlay imaging guidance, in addition to the application of the ALARA principles. The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile).

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female aged 18 or older, * Patients scheduled for aorto iliac endovascular revascularisation, * Pre-operative CT scan.

Exclusion criteria

* Women of childbearing age, * Absence of preoperative CT scan, * Emergency procedures.

Design outcomes

Primary

MeasureTime frameDescription
Dose area productThe end of the procedureDose area product (DAP) by the end of the procedure.

Secondary

MeasureTime frameDescription
Air KermaThe end of the procedureAir Kerma (mGy) by the end of the procedure.
Fluoroscopy timeThe end of the procedureFluoroscopy time (min) by the end of the procedure.
Number of DSA runsThe end of the procedureNumber of DSA runs by the end of the procedure.
Operative timeThe end of the procedureOperative time (min) by the end of the procedure.
Operator exposureThe end of the procedureOperator exposure (Sv) by the end of the procedure.
Contrast volumeThe end of the procedureContrast volume (ml) by the end of the procedure.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026